(Q51615023)

English

Vascular effects of linagliptin in non-obese diabetic mice are glucose-independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin-1 (CAV-1) pathway.

scientific article published on 27 July 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

Vascular effects of linagliptin in non-obese diabetic mice are glucose-independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin-1 (CAV-1) pathway. (English)

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

0 references

1 reference

based on heuristic

inferred from title

Danilo Swann Matassa

5

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

Franca Esposito

7

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

Vincenzo Brancaleone

object named as

Vincenzo Brancaleone

4

0 references

author name string

Valentina Vellecco

1

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

Emma Mitidieri

2

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

Antonella Gargiulo

3

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

Thomas Klein

6

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

Giuseppe Cirino

8

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

Mariarosaria Bucci

9

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

publication date

27 July 2016

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

18

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

12

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

1236-1243

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

The biology of incretin hormones

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Pharmacology, physiology, and mechanisms of incretin hormone action

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Effect of heart failure on dipeptidyl peptidase IV activity in plasma of dogs.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

A fluorometric assay for the measurement of nitrite in biological samples.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

ACE-inhibition ameliorates vascular reactivity and delays diabetes outcome in NOD mice.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Major occurrence of the new alpha2beta1 isoform of NO-sensitive guanylyl cyclase in brain

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

eNOS at a glance

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Nitric oxide (NO) primarily accounts for endothelium-dependent component of beta-adrenoceptor-activated smooth muscle relaxation of mouse aorta in response to isoprenaline

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Role of G(i/o)-Src kinase-PI3K/Akt pathway and caveolin-1 in β₂-adrenoceptor coupling to endothelial NO synthase in mouse pulmonary artery.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Signal transduction of eNOS activation

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Nitric oxide synthases: regulation and function

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12750

21 January 2018

Identifiers

10.1111/DOM.12750

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

1 reference

Europe PubMed Central

8 April 2018

http://europepmc.org/abstract/MED/27460695

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51615023&oldid=1518366304"